Hiam Chemaitelly

Hiam Chemaitelly

Auto-generated profile, based on publicly available information

Hiam Chemaitelly

Infectious Disease Epidemiology Group, Weill Cornell Medicine - Qatar, Cornell University, Doha, Qatar

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2019 in Research Synthesis Methods
Verified
Journal Article
Open access
PDF file
GSGuido Schwarzer
Guido Schwarzer
HCHiam Chemaitelly
Hiam Chemaitelly
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad
GRGerta Rucker
Gerta Rucker
Standard generic inverse variance methods for the combination of single proportions are based on transformed proportions using the logit, arcsine, and Freeman‐Tukey double arcsine transformations. Generalized linear mixed models are another more elaborate approach. Irrespective of the approach, meta‐analysis results are typically back‐transformed to the original scale in order to ease interpretation. Whereas the back‐transformation of meta‐analysis results is straightforward for most transformations, this is not the case for the Freeman‐Tukey double arcsine transformation, albeit possible.In this case study with five studies, we demonstrate how seriously misleading the back‐transformation of the Freeman‐Tukey double arcsine transformation can be. We conclude that this transformation should only be used with special caution for the meta‐analysis of single proportions due to potential problems with the back‐transformation. Generalized linear mixed models seem to be a promising alternative.

15 June 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
HAHeba N. Altarawneh
Heba N. Altarawneh
HCHiam Chemaitelly
Hiam Chemaitelly
HAHoussein Ayoub
Houssein Ayoub
PTPatrick Tang
Patrick Tang
MHMohammad R. Hasan
Mohammad R. Hasan
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad
The protection conferred by natural immunity, vaccination, and both against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the BA.1 or BA.2 sublineages of the omicron (B.1.1.529) variant is unclear. We conducted a national, matched, test-negative, case–control study in Qatar from December 23, 2021, through February 21, 2022, to evaluate the effectiveness of vaccination with BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna), natural immunity due to previous infection with variants other than omicron, and hybrid immunity (previous infection and vaccination) against symptomatic omicron infection and against severe, critical, or fatal coronavirus disease 2019 (Covid-19). The effectiveness of previous infection alone against symptomatic BA.2 infection was 46.1% (95% confidence interval [CI], 39.5 to 51.9). The effectiveness of vaccination with two doses of BNT162b2 and no previous infection was negligible (−1.1%; 95% CI, −7.1 to 4.6), but nearly all persons had received their second dose more than 6 months earlier. The effectiveness of three doses of BNT162b2 and no previous infection was 52.2% (95% CI, 48.1 to 55.9). The effectiveness of previous infection and two doses of BNT162b2 was 55.1% (95% CI, 50.9 to 58.9), and the effectiveness of previous infection and three doses of BNT162b2 was 77.3% (95% CI, 72.4 to 81.4). Previous infection alone, BNT162b2 vaccination alone, and hybrid immunity all showed strong effectiveness (>70%) against severe, critical, or fatal Covid-19 due to BA.2 infection. Similar results were observed in analyses of effectiveness against BA.1 infection and of vaccination with mRNA-1273. No discernable differences in protection against symptomatic BA.1 and BA.2 infection were seen with previous infection, vaccination, and hybrid immunity. Vaccination enhanced protection among persons who had had a previous infection. Hybrid immunity resulting from previous infection and recent booster vaccination conferred the strongest protection. (Funded by Weill Cornell Medicine–Qatar and others.)

2 November 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PTPatrick Tang
Patrick Tang
MHMohammad R. Hasan
Mohammad R. Hasan
HCHiam Chemaitelly
Hiam Chemaitelly
HYHADI YASSINE
HADI YASSINE
FBFatiha Benslimane
Fatiha Benslimane
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad

9 July 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
HCHiam Chemaitelly
Hiam Chemaitelly
HYHADI YASSINE
HADI YASSINE
FBFatiha M. Benslimane
Fatiha M. Benslimane
HKHebah A. Al Khatib
Hebah A. Al Khatib
PTPatrick Tang
Patrick Tang
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad

2 June 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
HCHiam Chemaitelly
Hiam Chemaitelly
HAHoussein Ayoub
Houssein Ayoub
SASawsan AlMukdad
Sawsan AlMukdad
PCPeter Coyle
Peter Coyle
PTPatrick Tang
Patrick Tang
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad
SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 vaccines against BA.1 and BA.2 infections in Qatar. BNT162b2 effectiveness was highest at 46.6% (95% CI: 33.4–57.2%) against symptomatic BA.1 and at 51.7% (95% CI: 43.2–58.9%) against symptomatic BA.2 infections in the first three months after the second dose, but declined to ~10% or below thereafter. Effectiveness rebounded to 59.9% (95% CI: 51.2–67.0%) and 43.7% (95% CI: 36.5–50.0%), respectively, in the first month after the booster dose, before declining again. Effectiveness against COVID-19 hospitalization and death was 70–80% after the second dose and >90% after the booster dose. mRNA-1273 vaccine protection showed similar patterns. mRNA vaccines provide comparable, moderate, and short-lived protection against symptomatic BA.1 and BA.2 Omicron infections, but strong and durable protection against COVID-19 hospitalization and death.

26 January 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SKSilva P. Kouyoumjian
Silva P. Kouyoumjian
HCHiam Chemaitelly
Hiam Chemaitelly
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad
Egypt is the most affected nation by hepatitis C virus (HCV) and needs a comprehensive characterization of HCV epidemiology to inform the scale-up of treatment and prevention programs. Systematic reviews, meta-analyses, and meta-regressions were conducted. A total of 25 incidence, 259 prevalence, and 47 genotype studies were identified. Incidence and prevalence levels were high across all populations. Genotype 4 accounted for 94.1% of infections with a relative Shannon Diversity Index of only 14.4%. Pooled mean HCV prevalence was estimated at 11.9% (95% CI = 11.1–12.6%) among the general population, 55.6% (95% CI = 49.4–61.7%) among populations at high risk, 14.3% (95% CI = 10.3–18.8%) among populations at intermediate risk, 56.0% (95% CI = 50.4–61.6%) among populations with liver-related conditions, and 35.0% (95% CI = 27.3–43.1%) among special clinical populations. Mean HCV viremic rate was estimated at 66.7% (95% CI = 61.7–71.5%). Meta-regression indicated 6% lower odds for HCV prevalence for each one-year increment in publication year (AOR = 0.94; 95% CI = 0.92–0.96). HCV prevalence is high with evidence for ongoing transmission mainly through healthcare. Genotype diversity is low with genotype 4 dominance. Two-thirds of antibody-positive Egyptians are chronically infected and need treatment. Clinical populations should be prioritized for screening. Despite the large-scale epidemic, prevalence appears to be declining rapidly consistent with a contracting epidemic.